Dysfunction of the hypothalamic-pituitary-adrenal axis in HIV infection and disease

Hormones

Volumn 7, Issue 3, 2008, Pages 205-216

  Zapanti, Evangelia ^a   Terzidis, Konstantinos ^a   Chrousos, George ^b  

^a ALEXANDRA HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

AIDS; Glucocorticoid hypersensitivity; Glucocorticoid resistance; HIV; HPA axis; Vpr

Indexed keywords

ANTIVIRUS AGENT; CYTOKINE; GLUCOCORTICOID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CORTICOSTEROID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADRENAL DISEASE; AUTOPSY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCORTISOLISM; HYPERSENSITIVITY; HYPOPHYSIS DISEASE; HYPOTHALAMUS DISEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NONHUMAN; REVIEW; ADRENAL INSUFFICIENCY; CUSHING SYNDROME; DRUG EFFECT; DRUG RESISTANCE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INSULIN RESISTANCE; PATHOGENICITY; PATHOPHYSIOLOGY; VIROLOGY;

ADRENAL CORTEX HORMONES; ADRENAL GLAND DISEASES; ADRENAL INSUFFICIENCY; ANTI-HIV AGENTS; CUSHING SYNDROME; DRUG RESISTANCE; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INSULIN RESISTANCE; PITUITARY-ADRENAL SYSTEM;

EID: 52449117162     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1200     Document Type: Review

References (96)

1. Chrousos GP, 1995 The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 332: 1351-1362.
2. Selye H, 1936 A Syndrome Produced by Diverse Nocuous Agents. Nature 138: 32.
3. Chrousos GP, Gold PW, 1992 The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 267: 1244-1252.
4. Rivier C, Brownstein M, Spiess J, Rivier J, Vale W, 1982 In vivo corticotropin-releasing factor-induced secretion of adrenocorticotropin, beta-endorphin, and corticosterone. Endocrinology 110: 272-278.
5. Conaglen JV, Donald RA, Espiner EA, Livesey JH, Nicholls MG, 1984 The effect of ovine corticotropin-releasing factor on catecholamine, vasopressin, and aldosterone secretion in normal man. J Clin Endocrinol Metab 58: 463-466. (Pubitemid 14166151)
6. Mastorakos G, Magiakou MA, Chrousos GP, 1995 Effects of the immune/inflammatory reaction on the hypothalamic-pituitary-adrenal axis. Ann N Y Acad Sci 1771: 438-448. (Pubitemid 26077425)
7. Mastorakos G, Karoutsou EI, Mizamtsidi M, 2006 Corticotropin releasing hormone and the immune/inflammatory response Eur J Endocrinol 155: Suppl 1: S77-S84
8. Mastorakos G, Ilias I, 2000 Relationship between interleukin-6 (IL-6) and hypothalamic-pituitary-adrenal axis hormones in rheumatoid arthritis. Z Rheumatol 59: Suppl 2: 75-79. (Pubitemid 30826113)
9. Imura H, Fukata J, Mori T, 1991 Cytokines and endocrine function: an interaction between the immune and neuroendocrine systems. Clin Endocrinol (Oxf) 35: 107-115.
10. Mastorakos G, Chrousos GP, Weber JS, 1993 Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 77: 1690-1694. (Pubitemid 24000936)
11. Mastorakos G, Weber JS, Magiakou MA, Gunn H, Chrousos GP, 1994 Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab 79: 934-939. (Pubitemid 24983158)
12. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY, 1993 Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol 151: 3460-3466. (Pubitemid 23282658)
13. Biglino A, Limone P, Forno B et al, 1995 Altered adrenocorticotropin and cortisol response to corticotropinreleasing hormone in HIV-1 infection. Eur J Endocrinol 133: 173-179.
14. Hilton CW, Harrington PT, Prasad C, Svec F, 1988 Adrenal insufficiency in the acquired immunodeficiency syndrome. South Med J 81: 1493-1495. (Pubitemid 19148226)
15. Raffi F, Brisseau JM, Planchon B, Remi JP, Barrier JH, Grolleau JY, 1991 Endocrine function in 98 HIV-infected patients: a prospective study. AIDS 5: 729-733.
16. Dobs AS, Dempsey MA, Ladenson PW, Polk BF, 1988 Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 84: 611-616.
17. Verges B, Chavanet P, Desgres J et al, 1989 Adrenal function in HIV infected patients. Acta Endocrinol (Copenh) 121: 633-637.
18. Villette JM, Bourin P, Doinel C, et al, 1990 Circadian variations in plasma levels of hypophyseal, adrenocortical and testicular hormones in men infected with human immunodeficiency virus. J Clin Endocrinol Metab 70: 572-577. (Pubitemid 20092426)
19. Membreno L, Irony I, Dere W, Klein R, Biglieri EG, Cobb E, 1987 Adrenocortical function in acquired immunodeficiency syndrome. J Clin Endocrinol Metab 65: 482-487. (Pubitemid 17131436)
20. Freda PU, Papadopoulos AD, Wardlaw SL, Goland RS, 1997 Spectrum of Adrenal Dysfunction in Patients with Acquired Immunodeficiency Syndrome - Evaluation of Adrenal and Pituitary Reserve with ACTH and Corticotropin- Releasing Hormone Testing. Trends Endocrinol Metab 8: 173-180.
21. Findling JW, Buggy BP, Gilson IH, Brummitt CF, Bernstein BM, Raff H, 1994 Longitudinal evaluation of adrenocortical function in patients infected with the human immunodeficiency virus. J Clin Endocrinol Metab 79: 1091-1096. (Pubitemid 24342253)
22. Schurmeyer TH, Muller V, von Zur MA, Schmidt RE, 1997 Thyroid and adrenal function in HIV-infected outpatients. Eur J Med Res 2: 220-226.
23. Raber J, Sorg O, Horn TF, et al, 1998 Inflammatory cytokines: putative regulators of neuronal and neuroendocrine function. Brain Res Brain Res Rev 26: 320-326. (Pubitemid 28318087)
24. Hashemi FB, Hughes TK, Smith EM, 1998 Human immunodeficiency virus induction of corticotropin in lymphoid cells. J Clin Endocrinol Metab 83: 4373-4381. (Pubitemid 29100138)
25. Costa A, Nappi RE, Polatti F, Poma A, Grossman AB, Nappi G, 2000 Stimulating effect of HIV-1 coat protein gp120 on corticotropin-releasing hormone and arginine vasopressin in the rat hypothalamus: involvement of nitric oxide. Exp Neurol 166: 376-384.
26. Norbiato G, Bevilacqua M, Vago T, et al, 1992 Cortisol resistance in acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74: 608-613.
27. Leung DY, Martin RJ, Szefler SJ, et al, 1995 Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J Exp Med 181: 33-40.
28. Leung DY, Hamid Q, Vottero A, et al, 1997 Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 186: 1567-1574. (Pubitemid 27479816)
29. Bamberger CM, Bamberger AM, de Castro M, Chrousos GP, 1995 Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 95: 2435-2441.
30. Charmandari E, Chrousos GP, Ichijo T, et al, 2005 The human glucocorticoid receptor (hGR) beta isoform suppresses the transcriptional activity of hGRalpha by interfering with formation of active coactivator complexes. Mol Endocrinol 19: 52-64. (Pubitemid 40065958)
31. Seney FD Jr, Burns DK, Silva FG, 1990 Acquired immunodeficiency syndrome and the kidney. Am J Kidney Dis 16: 1-13.
32. Sellmeyer DE, Grunfeld C, 1996 Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev 17: 518-532. (Pubitemid 26346641)
33. Stricker RB, Goldberg DA, Hu C, Hsu JW, Goldberg B, 1999 A syndrome resembling primary aldosteronism (Conn syndrome) in untreated HIV disease. AIDS 13: 1791-1792. (Pubitemid 30015735)
34. Grinspoon SK, Bilezikian JP, 1992 HIV disease and the endocrine system. N Engl J Med 327: 1360-1365.
35. Parker LN, Levin ER, Lifrak ET, 1985 Evidence for adrenocortical adaptation to severe illness. J Clin Endocrinol Metab 60: 947-952.
36. Zumoff B, Walsh BT, Katz JL, et al, 1983 Subnormal plasma dehydroisoandrosterone to cortisol ratio in anorexia nervosa: a second hormonal parameter of ontogenic regression. J Clin Endocrinol Metab 56: 668-672. (Pubitemid 13165428)
37. Grinspoon S, Corcoran C, Stanley T, Rabe J, Wilkie S, 2001 Mechanisms of androgen deficiency in human immunodeficiency virus-infected women with the wasting syndrome. J Clin Endocrinol Metab 86: 4120-4126. (Pubitemid 32848523)
38. Zumoff B, Walsh BT, Katz JL, et al, 1983 Subnormal plasma dehydroisoandrosterone to cortisol ratio in anorexia nervosa: a second hormonal parameter of ontogenic regression. J Clin Endocrinol Metab 56: 668-672. (Pubitemid 13165428)
39. Wisniewski TL, Hilton CW, Morse EV, Svec F, 1993 The relationship of serum DHEA-S and cortisol levels to measures of immune function in human immunodeficiency virus-related illness. Am J Med Sci 305: 79-83. (Pubitemid 23046460)
40. Christeff N, Gherbi N, Mammes O, et al, 1997 Serum cortisol and DHEA concentrations during HIV infection. Psychoneuroendocrinology 22: Suppl 1: 11-18. (Pubitemid 27380689)
41. Clerici M, Trabattoni D, Piconi S, et al, 1997 A possible role for the cortisol/anticortisols imbalance in the progression of human immunodeficiency virus. Psychoneuroendocrinology 22: Suppl 1: 27-31 (Pubitemid 27380691)
42. Araneo BA, Woods ML, Daynes RA, 1993 Reversal of the immunosenescent phenotype by dehydroepiandrosterone: hormone treatment provides an adjuvant effect on the immunization of aged mice with recombinant hepatitis B surface antigen. J Infect Dis 167: 830-840.
43. Eledrisi MS, Verghese AC, 2001 Adrenal insufficiency in HIV infection: a review and recommendations. Am J Med Sci 321: 137-144. (Pubitemid 32128792)
44. Salim YS, Faber V, Wiik A, Andersen PL, Hoier-Madsen M, Mouritsen S, 1988 Anti-corticosteroid antibodies in AIDS patients. APMIS 96: 889-894.
45. Putignano P, Kaltsas GA, Satta MA, Grossman AB, 1998 The effects of anti-convulsant drugs on adrenal function. Horm Metab Res 30: 389-397. (Pubitemid 28308016)
46. Kyriazopoulou V, Parparousi O, Vagenakis AG, 1984 Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. J Clin Endocrinol Metab 59: 1204-1206. (Pubitemid 15223360)
47. Ediger SK, Isley WL, 1988 Rifampicin-induced adrenal insufficiency in the acquired immunodeficiency syndrome: difficulties in diagnosis and treatment. Postgrad Med J 64: 405-406. (Pubitemid 18130655)
48. Leinung MC, Liporace R, Miller CH, 1995 Induction of adrenal suppression by megestrol acetate in patients with AIDS Ann Intern Med 122: 843-845.
49. Niedt GW, Schinella RA, 1985 Acquired immunodeficiency syndrome. Clinicopathologic study of 56 autopsies. Arch Pathol Lab Med 109: 727-734.
50. Tapper ML, Rotterdam HZ, Lerner CW, Al'Khafaji K, Seitzman PA, 1984 Adrenal necrosis in the acquired immunodeficiency syndrome. Ann Intern Med 100: 239-241. (Pubitemid 14188780)
51. Welch K, Finkbeiner W, Alpers CE, et al, 1984 Autopsy findings in the acquired immune deficiency syndrome. JAMA 252: 1152-1159. (Pubitemid 14067514)
52. Masharani U, Schambelan M, 1993 The endocrine complications of acquired immunodeficiency syndrome. Adv Intern Med 38: 323-336.
53. Mayo J, Collazos J, Martinez E, Ibarra S, 2002 Adrenal Function in the Human Immunodeficiency Virus-Infected Patient. Arch Intern Med 162: 1095-1098. (Pubitemid 34522393)
54. McKenzie R, Travis WD, Dolan SA, et al, 1991 The causes of death in patients with human immunodeficiency virus infection: a clinical and pathologic study with emphasis on the role of pulmonary diseases. Medicine (Baltimore) 70: 326-343.
55. Bricaire F, Marche C, Zoubi D, Regnier B, Saimot AG, 1988 Adrenocortical lesions and AIDS. Lancet 1: 881.
56. Hofbauer LC, Heufelder AE, 1996 Endocrine implications of human immunodeficiency virus infection. Medicine (Baltimore) 75: 262-278. (Pubitemid 26337846)
57. Freda PU, Bilezikian JP, 1999 The hypothalamus-pituitary-adrenal axis in HIV disease. AIDS Read 9: 43-50.
58. Koutkia P, Grinspoon S, 2004 HIV-Associated Lipodystrophy: Pathogenesis, Prognosis, Treatment, and Controversies. Annu Rev Med 55: 303-317. (Pubitemid 38316729)
59. Martinez E, Mocroft A, Garcia-Viejo MA, et al, 2001 Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357: 592-598. (Pubitemid 32179612)
60. Carr A, Samaras K, Burton S, et al, 1998 A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-F58. (Pubitemid 28190689)
61. Baril JG, Junod P, Leblanc R, et al, 2005 HIV-associated lipodystrophy syndrome: A review of clinical aspects. Can J Infect Dis Med Microbiol 16: 233-243. (Pubitemid 41367844)
62. Miller KK, Daly PA, Sentochnik D, 1998 Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis 27: 68. (Pubitemid 28334422)
63. Yanovski JA, Miller KD, Kino T, et al, 1999 Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 84: 1925-1931. (Pubitemid 30647011)
64. Carr A, Samaras K, Chisholm DJ, Cooper DA, 1998 Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351: 1881-1883. (Pubitemid 28279721)
65. Chen D, Misra A, Garg A, 2002 Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 87: 4845-4856. (Pubitemid 35331060)
66. Brinkman K, Smeitink JA, Romijn JA, Reiss P, 1999 Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354: 1112-1115. (Pubitemid 29452832)
67. Behrens GM, Boerner AR, Weber K, et al, 2002 Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J Clin Invest 110: 1319-1327. (Pubitemid 35285758)
68. Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS, 2003 Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 88: 627-636. (Pubitemid 36207802)
69. Coffinier C, Hudon SE, Farber, et al, 2007 HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells. Proc Natl Acad Sci USA 104: 13432-13437. (Pubitemid 47293962)
70. Tran H, Robinson S, Mikhailenko I, Strickland DK, 2003 Modulation of the LDL receptor and LRP levels by HIV protease inhibitors. J Lipid Res 44: 1859-1869. (Pubitemid 37356658)
71. Bastard JP, Caron M, Vidal H, et al, 2002 Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359: 1026-1031. (Pubitemid 34286541)
72. Gavrila A, Hsu W, Tsiodras S, et al, 2005 Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial. Clin Infect Dis 40: 745-749. (Pubitemid 40381352)
73. Lee J, Chan J, Sourlas E, Raptopoulos V, Mantzoros C, 2006 Recombinant Methionyl Human Leptin Therapy in Replacement Doses Improves Insulin Resistance and Metabolic Profile in Patients with Lipoatrophy and Metabolic Syndrome Induced by the Highly Active Antiretroviral Therapy J Clin Endocrinol Metab 91: 2605-2611.
74. Coffinier C, Hudon S, Lee R, et al, 2008 A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells. J Biol Chem 283: 9797-9804.
75. Norbiato G, Bevilacqua M, Vago T, Taddei A, Clerici, 1997 Glucocorticoids and the immune function in the human immunodeficiency virus infection: a study in hypercortisolemic and cortisol-resistant patients. J Clin Endocrinol Metab 82: 3260-3263.
76. Norbiato G, Bevilacqua M, Vago T, Clerici M, 1996 Glucocorticoids and interferon-alpha in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 81: 2601-2606. (Pubitemid 26240284)
77. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S, 1999 Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 84: 1932-1937. (Pubitemid 30647012)
78. Simpson DM, Bender AN, Farraye J, Mendelson SG, Wolfe DE, 1990 Human immunodeficiency virus wasting syndrome may represent a treatable myopathy. Neurology 40: 535-538. (Pubitemid 20117547)
79. Brown TT, Chu H, Wang Z, et al, 2007 Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy. AIDS 21: 1731-1738. (Pubitemid 47237560)
80. Kino T, Chrousos GP, 2001 Glucocorticoid and mineralocorticoid resistance/hypersensitivity syndromes. J Endocrinol 169: 437-445.
81. Wanke CA, 1999 Epidemiological and clinical aspects of the metabolic complications of HIV infection the fat redistribution syndrome. AIDS 13: 1287-1293.
82. Kino T, Chrousos GP, 2004 Human immunodeficiency virus type-1 accessory protein Vpr: a causative agent of the AIDS-related insulin resistance/ lipodystrophy syndrome? Ann N Y Acad Sci 1024: 153-167.
83. Emerman M, 1996 HIV-1, Vpr and the cell cycle. Curr Biol 6: 1096-1103.
84. Kino T, Gragerov A, Valentin A, et al, 2005 Vpr protein of human immunodeficiency virus type 1 binds to 14-3-3 proteins and facilitates complex formation with Cdc25C: implications for cell cycle arrest. J Virol 79: 2780-2787. (Pubitemid 40270555)
85. Sawaya BE, Khalili K, Gordon J, Taube R, Amini S, 2000 Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome. J Biol Chem 275: 35209-35214. (Pubitemid 30832539)
86. Andersen JL, Planelles V, 2005 The role of Vpr in HIV-1 pathogenesis. Curr HIV Res 3: 43-51.
87. Pavlakis GN 1996 The molecular biology of HIV-1. In: Devita VT, Hellman S, Rosenberg SA (eds) AIDS: Diagnosis, Treatment and Prevention. Lippincott Raven, Philadelphia; pp, 45-74.
88. Levy DN, Refaeli Y, Weiner DB, 1995 Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J Virol 69: 1243-1252.
89. Sherman MP, Schubert U, Williams SA, et al, 2002 HIV-1 Vpr displays natural protein-transducing properties: implications for viral pathogenesis. Virology 302: 95-105. (Pubitemid 35356858)
90. Kino T, Gragerov A, Kopp JB, Stauber RH, Pavlakis GN, Chrousos GP, 1999 The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor. J Exp Med 189: 51-62. (Pubitemid 29047026)
91. Heery DM, Kalkhoven E, Hoare S, Parker MG, 1997 A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387: 733-736. (Pubitemid 27270617)
92. Kino T, Gragerov A, Slobodskaya O, Tsopanomichalou M, Chrousos GP, Pavlakis GN, 2002 Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators. J Virol 76: 9724-9734. (Pubitemid 35006513)
93. Mirani M, Elenkov I, Volpi S, Hiroi N, Chrousos GP, Kino T, 2002 HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection. J Immunol 169: 6361-6368. (Pubitemid 36903484)
94. Shrivastav S, Kino T, Cunningham T, et al, 2008 Human Immunodeficiency Virus (HIV-1) viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor γ and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy Mol Endocrinol 22: 234-247.
95. Fawell S, Seery J, Daikh Y, et al, 1994 Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A 91: 664-668. (Pubitemid 24041462)
96. Kino T, Slobodskaya O, Pavlakis GN, Chrousos GP, 2002 Nuclear receptor coactivator p160 proteins enhance the HIV-1 long terminal repeat promoter by bridging promoter-bound factors and the Tat-P-TEFb complex. J Biol Chem 277: 2396-2405. (Pubitemid 34953260)